nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0411	0.332	CbGbCtD
Pimecrolimus—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0382	0.308	CbGbCtD
Pimecrolimus—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0175	0.142	CbGbCtD
Pimecrolimus—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0161	0.13	CbGbCtD
Pimecrolimus—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.011	0.0885	CbGbCtD
Pimecrolimus—Temsirolimus—ABCB1—peripheral nervous system neoplasm	0.00278	0.362	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—peripheral nervous system neoplasm	0.00245	0.319	CrCbGaD
Pimecrolimus—Sirolimus—ABCB1—peripheral nervous system neoplasm	0.00245	0.319	CrCbGaD
Pimecrolimus—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000714	0.0011	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.000713	0.0011	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.000713	0.0011	CcSEcCtD
Pimecrolimus—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.000713	0.0011	CcSEcCtD
Pimecrolimus—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000708	0.00109	CcSEcCtD
Pimecrolimus—Cough—Alitretinoin—peripheral nervous system neoplasm	0.000707	0.00109	CcSEcCtD
Pimecrolimus—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000698	0.00108	CcSEcCtD
Pimecrolimus—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000695	0.00107	CcSEcCtD
Pimecrolimus—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000695	0.00107	CcSEcCtD
Pimecrolimus—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000693	0.00107	CcSEcCtD
Pimecrolimus—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000693	0.00107	CcSEcCtD
Pimecrolimus—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.00069	0.00106	CcSEcCtD
Pimecrolimus—Erythema—Cisplatin—peripheral nervous system neoplasm	0.00069	0.00106	CcSEcCtD
Pimecrolimus—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000689	0.00106	CcSEcCtD
Pimecrolimus—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000689	0.00106	CcSEcCtD
Pimecrolimus—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000689	0.00106	CcSEcCtD
Pimecrolimus—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000689	0.00106	CcSEcCtD
Pimecrolimus—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000689	0.00106	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000685	0.00106	CcSEcCtD
Pimecrolimus—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000684	0.00105	CcSEcCtD
Pimecrolimus—Eye disorder—Etoposide—peripheral nervous system neoplasm	0.000679	0.00105	CcSEcCtD
Pimecrolimus—Flushing—Etoposide—peripheral nervous system neoplasm	0.000674	0.00104	CcSEcCtD
Pimecrolimus—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.000661	0.00102	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000661	0.00102	CcSEcCtD
Pimecrolimus—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000657	0.00101	CcSEcCtD
Pimecrolimus—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.000656	0.00101	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000654	0.00101	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000649	0.001	CcSEcCtD
Pimecrolimus—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000648	0.000999	CcSEcCtD
Pimecrolimus—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000648	0.000998	CcSEcCtD
Pimecrolimus—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000643	0.00099	CcSEcCtD
Pimecrolimus—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000643	0.00099	CcSEcCtD
Pimecrolimus—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000642	0.000989	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000637	0.000982	CcSEcCtD
Pimecrolimus—Oedema—Vincristine—peripheral nervous system neoplasm	0.000637	0.000982	CcSEcCtD
Pimecrolimus—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000634	0.000978	CcSEcCtD
Pimecrolimus—Infection—Vincristine—peripheral nervous system neoplasm	0.000633	0.000975	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000631	0.00287	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PTPN11—peripheral nervous system neoplasm	0.000631	0.00287	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000625	0.00285	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000625	0.000963	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—peripheral nervous system neoplasm	0.000624	0.000961	CcSEcCtD
Pimecrolimus—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000622	0.000959	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.00062	0.00282	CbGpPWpGaD
Pimecrolimus—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000617	0.000951	CcSEcCtD
Pimecrolimus—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000617	0.000951	CcSEcCtD
Pimecrolimus—Back pain—Etoposide—peripheral nervous system neoplasm	0.000611	0.000942	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00061	0.00094	CcSEcCtD
Pimecrolimus—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000609	0.000939	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PTPN11—peripheral nervous system neoplasm	0.000604	0.00275	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000602	0.000928	CcSEcCtD
Pimecrolimus—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000602	0.000927	CcSEcCtD
Pimecrolimus—MTOR—ErbB Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000598	0.00272	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000597	0.00092	CcSEcCtD
Pimecrolimus—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000597	0.00092	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	0.000595	0.00271	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000594	0.0027	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.000593	0.000915	CcSEcCtD
Pimecrolimus—MTOR—TSLP Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.00059	0.00269	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000589	0.000908	CcSEcCtD
Pimecrolimus—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000589	0.000908	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000583	0.000899	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000583	0.000898	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.00058	0.000894	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—peripheral nervous system neoplasm	0.000577	0.000889	CcSEcCtD
Pimecrolimus—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000572	0.000881	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000571	0.000879	CcSEcCtD
Pimecrolimus—MTOR—Insulin Signaling—PTPN11—peripheral nervous system neoplasm	0.00057	0.0026	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—NRAS—peripheral nervous system neoplasm	0.000569	0.00259	CbGpPWpGaD
Pimecrolimus—Face oedema—Epirubicin—peripheral nervous system neoplasm	0.000568	0.000876	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—PTPN11—peripheral nervous system neoplasm	0.000567	0.00258	CbGpPWpGaD
Pimecrolimus—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000565	0.000871	CcSEcCtD
Pimecrolimus—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000565	0.000871	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—PTPN11—peripheral nervous system neoplasm	0.000564	0.00257	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000564	0.00257	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000564	0.000869	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000564	0.000869	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000563	0.000868	CcSEcCtD
Pimecrolimus—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000563	0.000868	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—NTRK1—peripheral nervous system neoplasm	0.000562	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PTPN11—peripheral nervous system neoplasm	0.000562	0.00256	CbGpPWpGaD
Pimecrolimus—Infection—Cisplatin—peripheral nervous system neoplasm	0.000559	0.000862	CcSEcCtD
Pimecrolimus—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000559	0.000862	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—PTPN11—peripheral nervous system neoplasm	0.000559	0.00254	CbGpPWpGaD
Pimecrolimus—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000555	0.000855	CcSEcCtD
Pimecrolimus—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000555	0.000855	CcSEcCtD
Pimecrolimus—Rash—Topotecan—peripheral nervous system neoplasm	0.000554	0.000854	CcSEcCtD
Pimecrolimus—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000554	0.000854	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events—NRAS—peripheral nervous system neoplasm	0.000553	0.00252	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000552	0.000851	CcSEcCtD
Pimecrolimus—Cough—Etoposide—peripheral nervous system neoplasm	0.000552	0.00085	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTPN11—peripheral nervous system neoplasm	0.000551	0.00251	CbGpPWpGaD
Pimecrolimus—Headache—Topotecan—peripheral nervous system neoplasm	0.000551	0.000849	CcSEcCtD
Pimecrolimus—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00055	0.000848	CcSEcCtD
Pimecrolimus—Rash—Tretinoin—peripheral nervous system neoplasm	0.00055	0.000848	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00055	0.000847	CcSEcCtD
Pimecrolimus—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000549	0.000847	CcSEcCtD
Pimecrolimus—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000549	0.000847	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—peripheral nervous system neoplasm	0.000548	0.00249	CbGpPWpGaD
Pimecrolimus—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000547	0.000844	CcSEcCtD
Pimecrolimus—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000547	0.000843	CcSEcCtD
Pimecrolimus—Headache—Tretinoin—peripheral nervous system neoplasm	0.000546	0.000842	CcSEcCtD
Pimecrolimus—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000546	0.000842	CcSEcCtD
Pimecrolimus—Pain—Vincristine—peripheral nervous system neoplasm	0.000545	0.000839	CcSEcCtD
Pimecrolimus—Constipation—Vincristine—peripheral nervous system neoplasm	0.000545	0.000839	CcSEcCtD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—peripheral nervous system neoplasm	0.000544	0.00248	CbGpPWpGaD
Pimecrolimus—Rash—Melphalan—peripheral nervous system neoplasm	0.000543	0.000837	CcSEcCtD
Pimecrolimus—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000542	0.000836	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00054	0.000833	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000539	0.00245	CbGpPWpGaD
Pimecrolimus—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000537	0.000828	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000534	0.000824	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—NRAS—peripheral nervous system neoplasm	0.000534	0.00243	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—NRAS—peripheral nervous system neoplasm	0.000534	0.00243	CbGpPWpGaD
Pimecrolimus—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000532	0.00082	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000526	0.000811	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTPN11—peripheral nervous system neoplasm	0.000526	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PTPN11—peripheral nervous system neoplasm	0.000526	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PTPN11—peripheral nervous system neoplasm	0.000526	0.00239	CbGpPWpGaD
Pimecrolimus—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000526	0.00081	CcSEcCtD
Pimecrolimus—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000525	0.000809	CcSEcCtD
Pimecrolimus—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000525	0.000809	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	0.000523	0.00238	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000522	0.000805	CcSEcCtD
Pimecrolimus—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000522	0.000805	CcSEcCtD
Pimecrolimus—Nausea—Topotecan—peripheral nervous system neoplasm	0.000522	0.000805	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—CD34—peripheral nervous system neoplasm	0.000522	0.00238	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PTPN11—peripheral nervous system neoplasm	0.000521	0.00237	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000521	0.000803	CcSEcCtD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—AKT1—peripheral nervous system neoplasm	0.00052	0.00237	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.00052	0.00237	CbGpPWpGaD
Pimecrolimus—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000518	0.000798	CcSEcCtD
Pimecrolimus—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000518	0.000798	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PTPN11—peripheral nervous system neoplasm	0.000517	0.00235	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000516	0.000795	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000516	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PTPN11—peripheral nervous system neoplasm	0.000514	0.00234	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—peripheral nervous system neoplasm	0.000514	0.00234	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000513	0.000791	CcSEcCtD
Pimecrolimus—Infection—Etoposide—peripheral nervous system neoplasm	0.000513	0.00079	CcSEcCtD
Pimecrolimus—Nausea—Melphalan—peripheral nervous system neoplasm	0.000511	0.000788	CcSEcCtD
Pimecrolimus—MTOR—TSH signaling pathway—HRAS—peripheral nervous system neoplasm	0.000509	0.00232	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—HRAS—peripheral nervous system neoplasm	0.000509	0.00232	CbGpPWpGaD
Pimecrolimus—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000509	0.000784	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000509	0.000784	CcSEcCtD
Pimecrolimus—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000506	0.000779	CcSEcCtD
Pimecrolimus—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000503	0.000776	CcSEcCtD
Pimecrolimus—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000503	0.000776	CcSEcCtD
Pimecrolimus—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000502	0.000774	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000501	0.000772	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000501	0.00228	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PPP3R1—peripheral nervous system neoplasm	0.0005	0.00228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—ERBB2—peripheral nervous system neoplasm	0.000498	0.00227	CbGpPWpGaD
Pimecrolimus—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000497	0.000766	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000493	0.00224	CbGpPWpGaD
Pimecrolimus—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000492	0.000758	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000489	0.000754	CcSEcCtD
Pimecrolimus—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000488	0.000752	CcSEcCtD
Pimecrolimus—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000487	0.000751	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000487	0.00075	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—PTPN11—peripheral nervous system neoplasm	0.000487	0.00222	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000486	0.000749	CcSEcCtD
Pimecrolimus—MTOR—CDC42 signaling events—HRAS—peripheral nervous system neoplasm	0.000486	0.00221	CbGpPWpGaD
Pimecrolimus—Pain—Cisplatin—peripheral nervous system neoplasm	0.000482	0.000742	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00048	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—NRAS—peripheral nervous system neoplasm	0.00048	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—peripheral nervous system neoplasm	0.000477	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—peripheral nervous system neoplasm	0.000473	0.00215	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000473	0.00215	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000473	0.000728	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000471	0.000725	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000471	0.000725	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000469	0.00214	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000469	0.000723	CcSEcCtD
Pimecrolimus—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000468	0.000721	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000466	0.00212	CbGpPWpGaD
Pimecrolimus—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000464	0.000715	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000463	0.000714	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00046	0.000709	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	0.00046	0.00209	CbGpPWpGaD
Pimecrolimus—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000456	0.000703	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000455	0.00207	CbGpPWpGaD
Pimecrolimus—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000453	0.000699	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000453	0.000699	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000453	0.000699	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000453	0.000697	CcSEcCtD
Pimecrolimus—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000452	0.000697	CcSEcCtD
Pimecrolimus—MTOR—TSH signaling pathway—AKT1—peripheral nervous system neoplasm	0.00045	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—AKT1—peripheral nervous system neoplasm	0.00045	0.00205	CbGpPWpGaD
Pimecrolimus—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000449	0.000693	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—ERBB2—peripheral nervous system neoplasm	0.000448	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—NRAS—peripheral nervous system neoplasm	0.000446	0.00203	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—peripheral nervous system neoplasm	0.000446	0.00203	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—ERBB2—peripheral nervous system neoplasm	0.000446	0.00203	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000445	0.000686	CcSEcCtD
Pimecrolimus—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000445	0.000686	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.000445	0.00203	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—ERBB2—peripheral nervous system neoplasm	0.000444	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—NRAS—peripheral nervous system neoplasm	0.000443	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—ERBB2—peripheral nervous system neoplasm	0.000442	0.00201	CbGpPWpGaD
Pimecrolimus—Constipation—Etoposide—peripheral nervous system neoplasm	0.000441	0.00068	CcSEcCtD
Pimecrolimus—Pain—Etoposide—peripheral nervous system neoplasm	0.000441	0.00068	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000441	0.000679	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	0.000439	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—AKT1—peripheral nervous system neoplasm	0.000439	0.002	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000437	0.000674	CcSEcCtD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—peripheral nervous system neoplasm	0.000437	0.00199	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000436	0.000672	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—peripheral nervous system neoplasm	0.000435	0.00198	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—AKT1—peripheral nervous system neoplasm	0.000434	0.00198	CbGpPWpGaD
Pimecrolimus—MTOR—SREBP signalling—AKT1—peripheral nervous system neoplasm	0.000434	0.00198	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ENO2—peripheral nervous system neoplasm	0.000433	0.00197	CbGpPWpGaD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.00043	0.000662	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000428	0.00195	CbGpPWpGaD
Pimecrolimus—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000428	0.000659	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000425	0.000656	CcSEcCtD
Pimecrolimus—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000423	0.000653	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000422	0.00065	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000422	0.00065	CcSEcCtD
Pimecrolimus—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00042	0.000648	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000647	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000647	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CD55—peripheral nervous system neoplasm	0.000418	0.0019	CbGpPWpGaD
Pimecrolimus—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000417	0.000642	CcSEcCtD
Pimecrolimus—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000416	0.000642	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—HRAS—peripheral nervous system neoplasm	0.000416	0.00189	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—ERBB2—peripheral nervous system neoplasm	0.000416	0.00189	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—peripheral nervous system neoplasm	0.000416	0.00189	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—ERBB2—peripheral nervous system neoplasm	0.000416	0.00189	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000415	0.000639	CcSEcCtD
Pimecrolimus—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000414	0.000638	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—ERBB2—peripheral nervous system neoplasm	0.000412	0.00188	CbGpPWpGaD
Pimecrolimus—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00041	0.000632	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—peripheral nervous system neoplasm	0.000408	0.00186	CbGpPWpGaD
Pimecrolimus—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000408	0.000629	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000408	0.000629	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000408	0.000629	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000408	0.000629	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—ERBB2—peripheral nervous system neoplasm	0.000406	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000406	0.00185	CbGpPWpGaD
Pimecrolimus—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000405	0.000624	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000405	0.00184	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—HRAS—peripheral nervous system neoplasm	0.000405	0.00184	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000404	0.000623	CcSEcCtD
Pimecrolimus—MTOR—Disease—GNS—peripheral nervous system neoplasm	0.000402	0.00183	CbGpPWpGaD
Pimecrolimus—Rash—Vincristine—peripheral nervous system neoplasm	0.000402	0.000619	CcSEcCtD
Pimecrolimus—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000401	0.000618	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—peripheral nervous system neoplasm	0.000401	0.00183	CbGpPWpGaD
Pimecrolimus—Headache—Vincristine—peripheral nervous system neoplasm	0.000399	0.000615	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000396	0.00061	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000394	0.000607	CcSEcCtD
Pimecrolimus—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000393	0.000605	CcSEcCtD
Pimecrolimus—MTOR—IGF1R signaling cascade—HRAS—peripheral nervous system neoplasm	0.00039	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—HRAS—peripheral nervous system neoplasm	0.00039	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—peripheral nervous system neoplasm	0.000386	0.00176	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000385	0.000594	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—ERBB2—peripheral nervous system neoplasm	0.000385	0.00175	CbGpPWpGaD
Pimecrolimus—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.00038	0.000586	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00038	0.000586	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00038	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—NRAS—peripheral nervous system neoplasm	0.000379	0.00173	CbGpPWpGaD
Pimecrolimus—Nausea—Vincristine—peripheral nervous system neoplasm	0.000378	0.000583	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000378	0.000582	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000378	0.000582	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.000576	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000371	0.00169	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	0.000371	0.00169	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000368	0.00168	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000368	0.000567	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	0.000367	0.00167	CbGpPWpGaD
Pimecrolimus—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000367	0.000565	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000365	0.000563	CcSEcCtD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—peripheral nervous system neoplasm	0.000364	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—NRAS—peripheral nervous system neoplasm	0.000363	0.00165	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000363	0.00165	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000358	0.00163	CbGpPWpGaD
Pimecrolimus—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000358	0.000552	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.000357	0.00163	CbGpPWpGaD
Pimecrolimus—Rash—Cisplatin—peripheral nervous system neoplasm	0.000355	0.000547	CcSEcCtD
Pimecrolimus—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000355	0.000547	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000354	0.000546	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000354	0.000546	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000353	0.000544	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.000542	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—HRAS—peripheral nervous system neoplasm	0.000351	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	0.000351	0.0016	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00035	0.0016	CbGpPWpGaD
Pimecrolimus—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.00035	0.000539	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—SLC2A1—peripheral nervous system neoplasm	0.000349	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	0.000346	0.00158	CbGpPWpGaD
Pimecrolimus—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000343	0.000528	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000342	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—NRAS—peripheral nervous system neoplasm	0.000341	0.00155	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00034	0.000524	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000339	0.000523	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	0.000339	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	0.000338	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—NRAS—peripheral nervous system neoplasm	0.000336	0.00153	CbGpPWpGaD
Pimecrolimus—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000335	0.000516	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000334	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	0.000331	0.00151	CbGpPWpGaD
Pimecrolimus—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000328	0.000506	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.000505	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.000505	CcSEcCtD
Pimecrolimus—MTOR—PI-3K cascade—AKT1—peripheral nervous system neoplasm	0.000328	0.00149	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	0.000327	0.00149	CbGpPWpGaD
Pimecrolimus—Rash—Etoposide—peripheral nervous system neoplasm	0.000325	0.000501	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000325	0.000501	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—HRAS—peripheral nervous system neoplasm	0.000324	0.00148	CbGpPWpGaD
Pimecrolimus—Headache—Etoposide—peripheral nervous system neoplasm	0.000323	0.000498	CcSEcCtD
Pimecrolimus—MTOR—PI3K/AKT activation—AKT1—peripheral nervous system neoplasm	0.00032	0.00146	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—AKT1—peripheral nervous system neoplasm	0.000317	0.00145	CbGpPWpGaD
Pimecrolimus—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000317	0.000489	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CD34—peripheral nervous system neoplasm	0.000317	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—NRAS—peripheral nervous system neoplasm	0.000316	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	0.000316	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	0.000316	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	0.000316	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	0.000313	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	0.000311	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	0.00031	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	0.00031	0.00141	CbGpPWpGaD
Pimecrolimus—Cough—Epirubicin—peripheral nervous system neoplasm	0.000309	0.000477	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	0.000309	0.00141	CbGpPWpGaD
Pimecrolimus—Nausea—Etoposide—peripheral nervous system neoplasm	0.000306	0.000472	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	0.000305	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000305	0.00139	CbGpPWpGaD
Pimecrolimus—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000302	0.000465	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000462	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—NRAS—peripheral nervous system neoplasm	0.000293	0.00133	CbGpPWpGaD
Pimecrolimus—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000446	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000446	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.000288	0.00131	CbGpPWpGaD
Pimecrolimus—Infection—Epirubicin—peripheral nervous system neoplasm	0.000287	0.000443	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.000441	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000437	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000283	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000282	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PPP3R1—peripheral nervous system neoplasm	0.000281	0.00128	CbGpPWpGaD
Pimecrolimus—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000433	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.00028	0.00127	CbGpPWpGaD
Pimecrolimus—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.00043	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	0.000277	0.00126	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000427	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000275	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	0.000273	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00027	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NCAM1—peripheral nervous system neoplasm	0.000269	0.00123	CbGpPWpGaD
Pimecrolimus—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000268	0.000412	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000268	0.000412	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.00041	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	0.000265	0.00121	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000406	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000263	0.0012	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000262	0.000404	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.000261	0.00119	CbGpPWpGaD
Pimecrolimus—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000401	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00026	0.0004	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000258	0.000397	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000257	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—HRAS—peripheral nervous system neoplasm	0.000251	0.00114	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000385	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	0.00025	0.00114	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000248	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	0.000248	0.00113	CbGpPWpGaD
Pimecrolimus—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000381	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000381	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	0.000247	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—HRAS—peripheral nervous system neoplasm	0.000246	0.00112	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	0.000245	0.00112	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000376	CcSEcCtD
Pimecrolimus—MTOR—Disease—ENO2—peripheral nervous system neoplasm	0.000244	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	0.000242	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	0.000241	0.0011	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.00037	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000239	0.000368	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000236	0.000364	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	0.000234	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000232	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	0.000231	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—peripheral nervous system neoplasm	0.000231	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	0.000231	0.00105	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000356	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.000231	0.00105	CbGpPWpGaD
Pimecrolimus—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000354	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	0.000229	0.00104	CbGpPWpGaD
Pimecrolimus—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000353	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000353	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000352	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000352	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	0.000227	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	0.000226	0.00103	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000225	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—peripheral nervous system neoplasm	0.000221	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	0.00022	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000219	0.000998	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	0.000219	0.000998	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000337	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	0.000218	0.000993	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	0.000217	0.000988	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.000215	0.000981	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000215	0.000977	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—peripheral nervous system neoplasm	0.000214	0.000975	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	0.000214	0.000974	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000214	0.000972	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000328	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000328	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000326	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000326	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IFNB1—peripheral nervous system neoplasm	0.000211	0.000962	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000205	0.000933	CbGpPWpGaD
Pimecrolimus—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000205	0.000315	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000204	0.00093	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	0.000204	0.00093	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	0.000204	0.00093	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	0.000204	0.00093	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	0.000202	0.000922	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	0.000201	0.000913	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	0.0002	0.000909	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000305	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000304	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000197	0.000897	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000197	0.000896	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC2A1—peripheral nervous system neoplasm	0.000196	0.000895	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	0.000196	0.000893	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTPN11—peripheral nervous system neoplasm	0.000195	0.000889	CbGpPWpGaD
Pimecrolimus—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000189	0.000292	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—AKT1—peripheral nervous system neoplasm	0.000189	0.000861	CbGpPWpGaD
Pimecrolimus—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000283	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000282	CcSEcCtD
Pimecrolimus—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000183	0.000833	CbGpPWpGaD
Pimecrolimus—Rash—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000281	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000281	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000279	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000181	0.000824	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—peripheral nervous system neoplasm	0.000176	0.0008	CbGpPWpGaD
Pimecrolimus—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000265	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000262	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.00026	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.00026	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000258	CcSEcCtD
Pimecrolimus—MTOR—Immune System—HGF—peripheral nervous system neoplasm	0.000163	0.000743	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	0.000161	0.000735	CbGpPWpGaD
Pimecrolimus—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000245	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	0.000158	0.000717	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	0.000155	0.000706	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—peripheral nervous system neoplasm	0.000154	0.000703	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000148	0.000674	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	0.000139	0.000633	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000137	0.000623	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000127	0.000576	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000124	0.000563	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—peripheral nervous system neoplasm	0.000123	0.000559	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000121	0.000549	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPN11—peripheral nervous system neoplasm	0.000119	0.000542	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	0.000118	0.000537	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—peripheral nervous system neoplasm	0.000117	0.000535	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000111	0.000504	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTPN11—peripheral nervous system neoplasm	0.00011	0.0005	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—peripheral nervous system neoplasm	0.000109	0.000498	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000108	0.000492	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.81e-05	0.000447	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—peripheral nervous system neoplasm	9.4e-05	0.000428	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.99e-05	0.000409	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	8.94e-05	0.000407	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—peripheral nervous system neoplasm	8.68e-05	0.000395	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.63e-05	0.000393	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—peripheral nervous system neoplasm	8.59e-05	0.000391	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	8.57e-05	0.00039	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	8.25e-05	0.000376	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.23e-05	0.000374	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.94e-05	0.000361	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.69e-05	0.00035	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.66e-05	0.000349	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.62e-05	0.000347	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—peripheral nervous system neoplasm	7.59e-05	0.000345	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—peripheral nervous system neoplasm	7.16e-05	0.000326	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—peripheral nervous system neoplasm	6.61e-05	0.000301	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.29e-05	0.000286	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—peripheral nervous system neoplasm	6.15e-05	0.00028	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.08e-05	0.000277	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.02e-05	0.000274	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.52e-05	0.000251	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	5.42e-05	0.000247	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.31e-05	0.000242	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—peripheral nervous system neoplasm	5.23e-05	0.000238	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—peripheral nervous system neoplasm	4.83e-05	0.00022	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.63e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—peripheral nervous system neoplasm	4.62e-05	0.00021	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	4.58e-05	0.000208	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.36e-05	0.000199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.31e-05	0.000196	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	4.3e-05	0.000196	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—peripheral nervous system neoplasm	4.27e-05	0.000194	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.54e-05	0.000161	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.51e-05	0.00016	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.45e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.38e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.99e-05	0.000136	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	9.48e-06	4.32e-05	CbGpPWpGaD
